Clinical trial CAEL101-301
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment- Naïve Patients with Mayo Stage IIIb AL Amyloidosis
| Cancers | |
|---|---|
| Organ | Amyloidose |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Caelum Biosciences, Inc. |
| EudraCT Identifier | 2019-004254-28 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04512235 |
| Inclusion criteria | Stage Mayo IIIb |
| Last update |